Oncodetect™ Molecular Residual Disease test

The highly sensitive1 Oncodetect Molecular Residual Disease (MRD) test can find subtle signs of residual cancer throughout the patient care journey. MRD tests can detect cancer recurrence and help inform personalized treatment options.

For providers

Help guide your patients with solid tumor cancers* using insights to inform adjuvant therapy, monitor for recurrence, and assess response to treatment.

For patients

Learn how personalized results can help you and your health care provider make more informed decisions about your treatment path.
Explore the science

Signs of cancer can be hard to find. The Oncodetect MRD test makes them hard to miss.

Dark gray DNA helixes with an orange circle around one gold helix.

What is Molecular Residual Disease?

Molecular Residual Disease (MRD) can be shed by cancer cells into the bloodstream in the form of tumor-specific DNA, also called circulating tumor DNA or ctDNA. This can happen during or after cancer treatment.

  • The presence of ctDNA may indicate that cancer is present in the body, even when not detected by current standard of care methods.2
  • ctDNA contains unique variants that can be detected by highly sensitive tests, offering real-time measurement of the disease burden.4
  • The detection and monitoring of MRD can help inform treatment decisions.
A doctor smiling while talking with a patient.

Detect cancer early to empower treatment decisions

The Oncodetect MRD test looks for minute signs of cancer related to a specific tumor. This kind of MRD testing allows you to detect cancer recurrence or progression earlier than with current standard methods,1,2 as well as monitor the disease over time.

Earlier detection and monitoring can help patients and providers:

  • Determine whether any cancer is detectable post-surgery, or if further treatment is necessary.1
  • Assess whether the cancer is likely to come back.1
  • Learn how cancer is responding to treatment.1
An Exact Sciences employee smiling while standing in a laboratory setting.



Innovation you can trust

At Exact Sciences, we’re dedicated to helping patients and providers make the most informed decisions in cancer prevention, treatment, and monitoring, by harnessing the latest innovations in screening and detection.

With more than 20 years of experience in genomic oncology, we’ve empowered over 1.8 million patients† living with cancer. We have invested in the latest MRD technologies and will continue to advance this field for the benefit of the patient and clinician.

With the Oncodetect MRD test, you get highly sensitive ctDNA detection,1 meaningful insights to help make timely treatment decisions, and the exceptional customer support Exact Sciences is known for.

The Oncodetect MRD test can detect cancer recurrence more than 2 years earlier than imaging.1

The Oncodetect MRD test provides residual disease detection and monitoring, allowing you to make more informed treatment decisions.

Highly personalized, highly sensitive1

By tracking up to 200 variants specific to a patient’s tumor, the Oncodetect MRD test grants more opportunities to detect ctDNA in the blood.1,5 A high level of sensitivity and specificity can help providers and patients assess whether cancer is remaining in the body, recurring, or is responding to specific treatment.
91%

In the surveillance setting, the Oncodetect MRD test correctly identified 91% of patients with stage III colorectal cancer whose cancer would recur.1

94%

In the surveillance setting, the Oncodetect MRD test correctly identified 94% of patients with stage III colorectal cancer whose cancer would not recur.1

78%

In the post-surgical setting, the Oncodetect MRD test correctly identified 78% of colorectal cancer patients whose cancer would recur.1

Have questions?

Call us at +1 866-662-6897.

References and footnotes

  1. Diergaarde B, Young G, Hall DW, Mazloom A, Costa G, Subramaniam S, Palomares M, Garces J, Baehner FL, Schoen RE; and other members of the Exact Sciences MRD Group. Circulating tumor DNA as a marker of recurrence risk in Stage III colorectal cancer: The α‐CORRECT study. Journal of Surgical Oncology.
  2. Centers for Medicare & Medicaid Services, Medicare Coverage Database. LCD—MolDX: Minimal Residual Disease Testing for Cancer. Accessed January 21, 2025. https://www.cms.gov/
  3. Cohen SA, et al. Nature. 2023;619(7969):259-268.
  4. Sanchez-Herrero E, et. al. Front Oncol. 2022.
  5. Santonja et al. EMBO. 2023. https://www.embopress.org/doi/full/10.15252/emmm.202216505
  6. The test has been validated in patients with stage II-IV colorectal cancer and Exact Sciences is currently pursuing applications in additional disease ontologies.
  7. Data on file as of 03/2025 at Genomic Health, Inc. 


    This test was developed, and its performance characteristics determined by Genomic Health, Inc. The Oncodetect test was clinically validated in colorectal cancer patients with stage II-IV disease. Performance characteristics may not apply in tumor types not included in this test’s clinical validation. The test has not been cleared or approved by the US Food and Drug Administration. The test has been validated as a Laboratory Developed Test per institutional and applicable CLIA regulation (CLIA# 03D2048606) and College of American Pathology (CAP# 8869063) as qualified to perform high complexity clinical laboratory testing.